BL-B01D1 is an anti-EGFR/anti-HER3 antibody–drug conjugate that binds EGFR on tumor cells, is internalized, and releases a cytotoxic payload (e.g., topoisomerase I inhibitor), causing DNA damage and tumor cell death, with potential bystander effect.